BioBeat16 will include a panel discussion on drawing out innovation in times of flux through the perspectives of pharma, biotech product development, investment and patient involvement. On the panel are:
Jane Osbourn, VP Research & Development, Head of Cambridge Site, MedImmune
Inga Deakin, Healthcare Ventures Associate, Imperial Innovations plc
Sally Waterman, Senior VP Corporate Development, Abzena plc
Julie Walter, Founder, Raremark
Chair: Lynn Drummond, Chair Venture Life Group and Infirst HEALTHCARE
BioBeat16 will be invaluable in you're working in academia, industry and finance and will provide an inrivalled opportunity for networking with those at the heart of biobusiness. The delegate cost is 拢10/person for academics, 拢30/person for business.
The event has generous support from this year's special partner, MedImmune, and sponsorship from AstraZeneca and Covington & Burling.
Space is limited, so please register today vie the BioBeat16 web page:
http://www.jbs.cam.ac.uk/biobeat2016
Jane Osbourn, VP Research & Development, Head of Cambridge Site, MedImmune
Inga Deakin, Healthcare Ventures Associate, Imperial Innovations plc
Sally Waterman, Senior VP Corporate Development, Abzena plc
Julie Walter, Founder, Raremark
Chair: Lynn Drummond, Chair Venture Life Group and Infirst HEALTHCARE
BioBeat16 will be invaluable in you're working in academia, industry and finance and will provide an inrivalled opportunity for networking with those at the heart of biobusiness. The delegate cost is 拢10/person for academics, 拢30/person for business.
The event has generous support from this year's special partner, MedImmune, and sponsorship from AstraZeneca and Covington & Burling.
Space is limited, so please register today vie the BioBeat16 web page:
http://www.jbs.cam.ac.uk/biobeat2016
